Daré Bioscience Tidigare resultatutveckling
Tidigare kriterier kontrolleras 0/6
Daré Bioscience har ökat intäkterna med en genomsnittlig årlig takt på 22.3%, medan Pharmaceuticals -branschen såg intäkterna växande på 7.4% årligen. Intäkterna har varit fallande med en genomsnittlig takt på 11.3% per år.
Viktig information
22.27%
Tillväxttakt i vinsten
42.32%
Tillväxttakt för EPS
| Pharmaceuticals Tillväxt i branschen | 5.95% |
| Intäkternas tillväxttakt | -11.30% |
| Avkastning på eget kapital | -471.37% |
| Nettomarginal | -1,300.66% |
| Nästa resultatuppdatering | 14 May 2026 |
Senaste uppdateringar av tidigare prestationer
Recent updates
Women’s Health Pipeline Risks Will Persist Yet Long Term Potential Will Eventually Emerge
Catalysts About Daré Bioscience Daré Bioscience develops women’s health products across sexual health, contraception, menopause, vaginal health and infectious disease, with a focus on differentiated formulations built around known compounds. What are the underlying business or industry changes driving this perspective?
Women’s Health Pipeline And Dual 503B Pathway Will Transform Long Term Earnings Potential
Catalysts About Daré Bioscience Daré Bioscience focuses on developing and commercializing women’s health products across sexual health, contraception and menopause. What are the underlying business or industry changes driving this perspective?
Women’s Health Platform And 503B Launches Will Reshape Long-Term Outlook
Catalysts About Daré Bioscience Daré Bioscience is a women's health company focused on developing and commercializing clinically supported products across sexual health, contraception, menopause and vaginal health. What are the underlying business or industry changes driving this perspective?We're A Little Worried About Daré Bioscience's (NASDAQ:DARE) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Is Daré Bioscience (NASDAQ:DARE) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Daré rises on positive data from early-to-mid-stage trial of intravaginal ring to treat menopause symptoms
Daré Bioscience (NASDAQ:DARE) is trading 6.5% higher after the company announced positive data from its Phase 1/2 clinical trial of investigational intravaginal ring, DARE-HRT1, to treat the vasomotor symptoms and genitourinary syndrome associated with menopause. The drug is designed to deliver bio-identical 17β-estradiol and bio-identical progesterone continuously over a 28-day period as part of a hormone therapy regimen. The topline data from the study showed improvement in both vasomotor symptoms as well as vaginal symptoms of menopause. The primary objective or the main goal of the study was to demonstrate the safety, tolerability, and pharmacokinetics (PK) of two different dose combinations over 12 weeks of use. The company said the levels of estradiol released from both the lower and higher dose formulation of DARE-HRT1 evaluated in the study achieved statistically significant improvement. Menopausal symptoms, including hot flashes and night sweats, were reduced compared with baseline in both DARE-HRT1 dose groups. The topline PK data from the study will be available later in Q4.Daré Bioscience rises as company submits application to begin trial of non-hormonal contraceptive
Daré Bioscience (NASDAQ:DARE) is trading 5.3% higher after the U.S. Food and Drug Administration approved its investigational device exemption (IDE) application to conduct an efficacy study of investigational hormone-free monthly intravaginal contraceptive, Ovaprene. The IDE approval will mean the FDA determined that the company provided sufficient data to support the initiation and conduct of the study. The submission included the results of the postcoital test clinical study of Ovaprene, in which the therapy prevented sperm from entering the cervical canal across all women and all cycles evaluated. The company is targeting mid-year 2023 to begin study recruitment.Dare Bioscience reports positive progress for cream for female sexual arousal disorder
Dare Bioscience (NASDAQ:DARE) said that based on an interim analysis of phase 2b data for its sildenafil cream for female sexual arousal disorder, enrollment in the study will complete in Q4. Total enrollment will be 150 women. The company anticipates a top-line data announcement in Q2 2023. Sildenafil is the active ingredient in Viagra, a pill approved for erectile dysfunction. Dare (DARE) noted that its sildenafil cream is designed to be applied to the vaginal tissue just prior to intercourse to increase blood flow directly to the tissue. Seeking Alpha Quant Rating views Dare (DARE) as a hold with high marks for growth and revisions.Daré Bioscience signs agreement with Organon for bacterial vaginosis therapy
Women health firm Daré Bioscience (NASDAQ:DARE) announced an exclusive license agreement with clinical-stage biopharma firm Organon (NYSE:OGN) to commercialize Xaciato, DARE's treatment of bacterial vaginosis in patients 12 years of age and older. Under the agreement, Daré will receive a $10M upfront payment from Organon and is eligible to receive potential milestone payments of up to $182.5M and tiered double-digit royalties based on net sales. Xaciato will be commercially available in the U.S. in Q4, DARE said. The companies entered into the agreement on March 31.Will Daré Bioscience (NASDAQ:DARE) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Diving Back Into Daré Bioscience Again
Today, we revisit women's health concern Daré Bioscience for the first time in nearly a year. This small cap concern just received its first FDA approval and is advancing other candidates in its pipeline. A full investment analysis follows in the paragraphs below.We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Why Daré Bioscience, Inc. (NASDAQ:DARE) Could Be Worth Watching
While Daré Bioscience, Inc. ( NASDAQ:DARE ) might not be the most widely known stock at the moment, it led the NASDAQCM...Fördelning av intäkter och kostnader
Hur Daré Bioscience tjänar och spenderar pengar. Baserat på senast rapporterade resultat, på rullande tolvmånadersbasis.
Resultat- och intäktshistorik
| Datum | Intäkter | Intäkter | G+A Kostnader | FoU-kostnader |
|---|---|---|---|---|
| 31 Dec 25 | 1 | -13 | 9 | 6 |
| 30 Sep 25 | 0 | -17 | 9 | -6 |
| 30 Jun 25 | 0 | -19 | 9 | -5 |
| 31 Mar 25 | 0 | -2 | 9 | 0 |
| 31 Dec 24 | 0 | -4 | 9 | 14 |
| 30 Sep 24 | 2 | -4 | 10 | -7 |
| 30 Jun 24 | 3 | -7 | 11 | -3 |
| 31 Mar 24 | 3 | -29 | 11 | -5 |
| 31 Dec 23 | 3 | -30 | 12 | 0 |
| 30 Sep 23 | 1 | -41 | 12 | 1 |
| 30 Jun 23 | 0 | -40 | 12 | -2 |
| 31 Mar 23 | 10 | -31 | 12 | -1 |
| 31 Dec 22 | 10 | -31 | 11 | 0 |
| 30 Sep 22 | 10 | -25 | 10 | 24 |
| 30 Jun 22 | 10 | -30 | 10 | 30 |
| 31 Mar 22 | 0 | -40 | 9 | 31 |
| 31 Dec 21 | 0 | -39 | 8 | 31 |
| 30 Sep 21 | 0 | -38 | 8 | 30 |
| 30 Jun 21 | 0 | -33 | 7 | 26 |
| 31 Mar 21 | 0 | -30 | 7 | 24 |
| 31 Dec 20 | 0 | -27 | 7 | 21 |
| 30 Sep 20 | 0 | -23 | 6 | 17 |
| 30 Jun 20 | 0 | -19 | 6 | 12 |
| 31 Mar 20 | 0 | -16 | 6 | 9 |
| 31 Dec 19 | 0 | -15 | 5 | 9 |
| 30 Sep 19 | 0 | -14 | 5 | 8 |
| 30 Jun 19 | 0 | -13 | 5 | 8 |
| 31 Mar 19 | 0 | -12 | 5 | 7 |
| 31 Dec 18 | 0 | -17 | 5 | 6 |
| 30 Sep 18 | 0 | -23 | 4 | 5 |
| 30 Jun 18 | 0 | -22 | 4 | 4 |
| 31 Mar 18 | 0 | -19 | 3 | 2 |
| 31 Dec 17 | 0 | -12 | 2 | 1 |
| 30 Sep 17 | 0 | -3 | 2 | 0 |
| 30 Jun 17 | 0 | -1 | 1 | 0 |
| 31 Mar 17 | 0 | -1 | 0 | 0 |
| 31 Dec 16 | 0 | -1 | 0 | 0 |
Kvalitetsintäkter: DARE är för närvarande olönsam.
Växande vinstmarginal: DARE är för närvarande olönsam.
Fritt kassaflöde vs resultatanalys
Analys av tidigare vinsttillväxt
Resultatutveckling: DARE är olönsam, men har minskat förlusterna under de senaste 5 åren med en hastighet av 22.3% per år.
Accelererande tillväxt: Det går inte att jämföra DARE s intäktstillväxt under det senaste året med dess 5-åriga genomsnitt eftersom det för närvarande är olönsamt
Resultat vs industri: DARE är olönsam, vilket gör det svårt att jämföra det senaste årets vinsttillväxt med Pharmaceuticals branschen ( -5% ).
Avkastning på eget kapital
Hög ROE: DARE har en negativ avkastning på eget kapital ( -471.37% ), eftersom det för närvarande är olönsamt.
Avkastning på tillgångar
Avkastning på sysselsatt kapital
Upptäck starka bolag som tidigare presterat bra
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/13 20:50 |
| Aktiekurs vid dagens slut | 2026/05/13 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Daré Bioscience, Inc. bevakas av 5 analytiker. 2 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Brian Kemp Dolliver | Brookline Capital Markets |
| Douglas Tsao | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |